. 2015 Oct 15;8(10):18954–18962.

Table 6.

Serum levels of sFas, sFasL, ALB, ALT, and TBIL in PLC patients after treatment

Group		Case	sFas (µg/L)	sFasL(μg/L)	ALB (g/L)	ALT (U/L)	TBIL (µmol/L)
Before treatment		40	52.26 ± 23.12	87.18 ± 27.12	34.26 ± 5.89	93.18 ± 60.12	52.18 ± 21.36
After BJOE/TACE combination therapy	1 m	40	103.68 ± 27.12^**	152.36 ± 28.12^**	35.12 ± 3.59	89.12 ± 36.78	43.26 ± 19.12
	3 m	40	31.28 ± 6.78^*,^##	83.56 ± 14.89^##	37.12 ± 5.36	67.28 ± 43.12	37.12 ± 18.86
	6 m	40	22.16 ± 3.12^**,^##,^&&	35.16 ± 5.18^**,^##,^&&	34.15 ± 4.51	59.18 ± 18.56	32.12 ± 20.18
After BJOE monotherapy	1 m	40	82.76 ± 25.16^**	140.36 ± 21.61^**	35.89 ± 3.96	91.28 ± 35.88	49.64 ± 20.08
	3 m	40	46.23 ± 10.96^*,^##	81.28 ± 14.89^##	36.08 ± 5.16	82.68 ± 42.04	43.28 ± 19.92
	6 m	40	40.22 ± 6.18^**,^##,^&&	70.08 ± 6.86^**,^##,^&&	34.28 ± 5.02	60.58 ± 19.86	39.58 ± 19.28
After TACE monotherapy	1 m	40	92.58 ± 23.06^**	146.72 ± 26.08^**	36.28 ± 3.08	90.12 ± 36.78	50.36 ± 18.66
	3 m	40	42.36 ± 7.26^*,^##	80.36 ± 13.78^##	35.36 ± 5.36	80.22 ± 38.66	45.32 ± 18.86
	6 m	40	38.28 ± 3.06^**,^##,^&&	62.28 ± 5.96^**,^##,^&&	34.69 ± 4.51	62.27 ± 20.36	42.38 ± 19.22

Abbreviations: sFas, soluble Fas receptor; sFasL, soluble Fas ligand; ALB, albumin; ALT, alanine aminotransferase; TBIL, total bilirubin. Note: Compared with before treatment;

P<0.05;

^**

P<0.01.

Compared with 1 m after treatment;

^##

P<0.01.

Compared with 3 m after treatment;

^&&

P<0.01.